U.S. Senator Marco Rubio (R-FL) joined Varney & Co. to discuss a suspected Russian plot against the United States and Canada. See below for highlights and watch the full interview on YouTube and Rumble. On reports of a Russian plot to place incendiary devices on...
News
Latest News
Rubio Calls Out PwC for Appeasing Communist China
The Chinese Communist Party (CCP) continues to increase scrutiny of Western auditing and consulting firms, including global consulting firm PricewaterhouseCoopers (PwC). Instead of distancing itself from Communist China, PwC has opted to strengthen its relationship...
ICYMI: Rubio Joins Face the Nation
U.S. Senator Marco Rubio (R-FL) joined Face the Nation to discuss the hacking of U.S. telecommunications companies by Communist China. See below for highlights and watch the full interview on YouTube and Rumble. On whether Chinese hackers have accessed the audio of...
Rubio, Rosen, Colleagues to Blinken: Designate Houthis as Foreign Terrorist Organization
The Houthis, backed by the Iranian regime, continue to escalate their attacks in the Middle East. Redesignating the Houthis as a Foreign Terrorist Organization (FTO) would impose meaningful costs on them and limit their ability to commit further acts of terrorism....
ICYMI: Rubio Joins Kudlow
U.S. Senator Marco Rubio (R-FL) joined Kudlow to discuss the October jobs report, the influence of illegal immigration on the workforce, and the Biden-Harris Administration’s economic policy failures. See below for highlights and watch the full interview on YouTube...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
ICYMI: Rubio To FDA: Don’t Yank Hope From Dying Children
Don’t Yank Hope From Dying Children
By Marco Rubio
STAT News
May 9, 2016
https://www.statnews.com/2016/05/09/rare-disease-duchenne-muscular-dystrophy-marco-rubio-fda/
The last couple of weeks have brought about an extraordinary display of strength from thousands of patients, parents, doctors, and friends on behalf of those with a rare disease called Duchenne muscular dystrophy, which causes a steady deterioration of muscle mass. By age 12, most boys with Duchenne have lost the ability to walk. The average life expectancy is about 25 years.
Last month, scores of these advocates flew to Washington, D.C., from around the country to attend a hearing of an FDA advisory committee that was set to rule on the viability of a promising new drug to treat Duchenne.
This committee was evaluating the results of a clinical trial of the drug that was conducted among a small group of people who have this disease. Those taking the drug have widely reported that it helped slow Duchenne’s progression and even led to some improvements in quality of life. This FDA advisory panel was meeting to decide whether to allow testing to expand and this drug to be more widely available.
They heard from an entire community of parents whose kids have Duchenne, who are seeing them improve, who know these kids better than any scientist, any doctor, any panelist at the FDA — and who begged for the drug to be approved. The committee, sadly, ruled against the drug. It did so because it essentially applied the same standard to this drug as it would to one designed to treat a much more common disease.
The committee should have instead focused on reviewing the drug in the context of a law passed in 2012 called the Food and Drug Administration Safety and Innovation Act, or FDASIA. It included multiple provisions to address the challenges of the rare disease patient community. In addition to having far fewer potential participants for drug studies, many rare diseases such as Duchenne are also 100 percent fatal, which means there are ethical concerns with giving any participant in a study a placebo.
One of the committee members who voted against the drug was later quoted as saying, “Based on all I heard, the drug definitely worked, but the question was framed differently.”
The FDA posed the question to this committee not by asking if the drug worked or not, but by asking about the process of the clinical trial. Did it have enough people? Was it conducted in the normal way? The drug’s trial, of course, did not meet the FDA’s normal standards, but only because it was not treating a normal condition.
Had the FDA utilized the various tools and authorities FDASIA grants to them to ease the evaluation of rare disease treatments, the committee very well may have reached a different conclusion. Instead, these patients and families are on the verge of losing access to the drug.
…
Keep reading here.